Blood Samples From Patients on a Clinical Trial to CINV During HSCT
Study Details
Study Description
Brief Summary
RATIONALE: Studying samples of blood in the laboratory from patients with cancer may help doctors learn more about nausea and vomiting caused by cancer treatment.
PURPOSE: This laboratory study is looking at blood samples from patients with cancer who were treated on a clinical trial to control nausea and vomiting during donor stem cell transplant.
| Condition or Disease | Intervention/Treatment | Phase |
|---|---|---|
|
Detailed Description
OBJECTIVES:
Primary
- To compare the amount of substance P in serum samples from patients with cancer treated with busulfan/cyclophosphamide or cyclophosphamide/total body irradiation conditioning regimens prior to undergoing allogeneic hematopoietic stem cell transplantation.
Secondary
- To assess the changes in substance P over time to see if there is an optimal time shown by this physiologic correlate to discontinue substance P blockade after the chemotherapy regimen is completed in these patients.
OUTLINE: Previously collected serum samples are analyzed by enzyme immunoassay for changes in substance P levels.
Patients' medical records are reviewed for demographic information, past history, and course of treatment.
Study Design
Outcome Measures
Primary Outcome Measures
- Average, median, and mode for substance P levels at different times []
Secondary Outcome Measures
- Correlation of substance P levels with patient response (emesis or not) []
Eligibility Criteria
Criteria
DISEASE CHARACTERISTICS:
-
Previously collected serum samples from patients with cancer enrolled on the placebo arm of the pilot aprepitant study
-
Patients treated with busulfan/cyclophosphamide or cyclophosphamide/total body irradiation conditioning regimens prior to undergoing allogeneic hematopoietic stem cell transplantation
PATIENT CHARACTERISTICS:
- Not specified
PRIOR CONCURRENT THERAPY:
- See Disease Characteristics
Contacts and Locations
Locations
| Site | City | State | Country | Postal Code | |
|---|---|---|---|---|---|
| 1 | OHSU Knight Cancer Institute | Portland | Oregon | United States | 97239-3098 |
Sponsors and Collaborators
- OHSU Knight Cancer Institute
- National Cancer Institute (NCI)
Investigators
- Principal Investigator: Joseph Bubalo, PharmD, BCPS, BCOP, OHSU Knight Cancer Institute
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- CDR0000617385
- P30CA069533
- OHSU-CPC-08055-L
- OHSU-IRB 4517
- MERCK-OHSU-CPC-08055-L